Table 4

Results of joint analysis

Gene/polymorphismCasesStudies combinedRisk groupH1 vs H0OR95% CIa
χ2 (df)P
COMT Val158MetAll cases (39 , 51 , 60) Val/Met 2.14 (2)0.340.880.75–1.05
Met/Met0.860.67–1.09
COMT Val158MetPre-men (39 , 60) Val/Met 0.25 (2)0.880.960.76–1.23
Met/Met0.910.63–1.31
COMT Val158MetPost-men (39 , 60) Val/Met 2.69 (2)0.260.830.66–1.04
Val/Val 0.820.59–1.13
CYP17 promoter T → CAll cases (29 , 30 , 35 , 62) C carrier1.28 (1)0.261.100.93–1.30
CYP17 promoter T → CAdvanced cases (29 , 30 , 35 , 62) C carrier1.48 (1)0.221.280.86–1.91
CYP19 (TTTA)nAll cases (32 , 37 , 55 , 65) (TTTA)12 carrier1.98 (1)0.161.260.91–1.74
CYP19 (TTTA)nAll cases (32 , 55 , 65) (TTTA)10 carrier9.62 (1)0.0022.331.36–4.17Evidence for heterogeneity (χ2 = 5.34; P = 0.069)
ER CCC325CCGAll cases (42 , 58) CG 4.74 (2)0.091.341.02–1.76
GG1.250.68–2.23
G carriers2.29 (1)1.250.94–1.68
PR PROGINSAll cases (31 , 38 , 48) T1/T2 4.97 (2)0.080.970.73–1.28
T2/T20.410.15–0.95
CYP1A1 Ile462ValAll cases (23 , 41 , 59) Val carrier0.14 (1)0.710.940.68–1.30Val/Val homozygotes rare
CYP1A1 3′ UTR T6235CAll Caucasian (23 , 41 , 59) C carrier1.71 (1)0.191.200.91–1.58CC homozygotes rare
CYP1A1 3′ UTR T6235CAll African-American (23 , 59) TC het1.30 (2)0.520.970.54–1.73
CC hom1.720.56–4.69
CYP2D6 All cases (24 , 36 , 45 , 46 , 53 , 57) Poor metabolizer0.081.360.96–1.91
GSTM1 deletionAll cases (23 , 34 , 44 , 64) Null2.66 (1)0.101.140.97–1.35
GSTM1 deletionPre-men (26 , 34) Null0.05 (1)0.830.960.70–1.34
GSTM1 deletionPost-men (20 , 26 , 34) Null4.11 (1)0.041.331.01–1.76Evidence for heterogeneity (χ2 = 6.21, 2 df; P = 0.045)
GST1 deletionAll Caucasian (23 , 34) Null0.75 (1)0.391.180.81–1.73
GSTP1 Ile105ValAll cases (33 , 34) Ile/Val 6.52 (2)0.041.611.10–2.34No evidence for heterogeneity
Val/Val1.830.95–4.48 (χ2 = 0.16; P = 0.69)
Val carrier5.42 (1)0.021.601.08–2.39No evidence for heterogeneity (χ2 = 0.03; P = 0.86)
NAT1 All cases (50 , 63) T carrier0.24 (1)0.631.070.82–1.39
NAT2 All cases (19 , 21 , 40 , 50) Slow acetylator0.15 (1)0.700.970.84–1.13
NAT2 Pre-men case (21 , 50) Slow acetylator0.085 (1)0.771.050.78–1.40
NAT2 Post-men cases (21 , 50) Slow acetylator0.61 (1)0.440.900.69–1.17
TP53 Arg72ProAll cases (43 , 56 , 61) Arg/Pro 4.64 (2)0.101.231.02–1.58
Pro/Pro1.120.74–1.65
Pro carrier4.52 (1)0.031.271.02–1.59
TP53 intron 6 A → G (49 , 52 , 56 , 61) AG 1.95 (2)0.381.160.91–1.47
AA0.840.32–1.79
TP53 intron 16-bp insertion (43 , 56 , 61) A1/A2 0.16 (2)0.921.020.79–1.31
A2/A2 0.890.39–1.79
  • a CI, confidence interval; Pre-men, premenopausal; Post-men, postmenopausal; het, heterozygote; hom, homozygote.